Teva files IND for new MS treatment

Teva and Switzerland's Active Biotech have filed an IND for laquinimod for relapsing forms of multiple sclerosis. Laquinimod is a novel orally administered immunomodulatory substance developed by Active Biotech and recently licensed to Teva. A Phase III trial of the drug is scheduled to get started in 2006. "I am pleased to report on this significant milestone," said Israel Makov, president and CEO of Teva. "This IND filing is an important step towards the initiation of pivotal studies with laquinimod which, along with Teva's development of an oral form of Copaxone, enhance the likelihood that Teva will be the first to market an oral treatment."

- read this press release for more

ALSO: The FDA has granted Teva tentative approval for its generic version of Aventis' Amaryl tablets for diabetes. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.